Shiv O’neill Purchases 3,998 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) insider Shiv O’neill purchased 3,998 shares of Elanco Animal Health stock in a transaction dated Tuesday, August 18th. The stock was bought at an average price of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Elanco Animal Health Stock Performance

Shares of ELAN traded up $0.02 during mid-day trading on Tuesday, hitting $23.63. 5,080,159 shares of the company traded hands, compared to its average volume of 5,750,406. The stock has a market cap of $11.80 billion, a price-to-earnings ratio of -57.63, a P/E/G ratio of 1.42 and a beta of 1.67. The stock has a 50-day moving average price of $24.56 and a two-hundred day moving average price of $24.01. Elanco Animal Health Incorporated has a 1 year low of $17.11 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05.

Get Elanco Animal Health alerts:

Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ELAN. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. KeyCorp increased their price objective on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Citigroup raised their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Finally, JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Read Our Latest Stock Analysis on Elanco Animal Health

Institutional Trading of Elanco Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of ELAN. Peak Retirement Planning Inc. purchased a new stake in Elanco Animal Health in the 4th quarter worth approximately $2,756,000. Norges Bank purchased a new position in Elanco Animal Health during the fourth quarter valued at approximately $32,415,000. Allspring Global Investments Holdings LLC bought a new position in shares of Elanco Animal Health in the first quarter worth approximately $66,390,000. Geneos Wealth Management Inc. boosted its position in shares of Elanco Animal Health by 3,358.1% in the first quarter. Geneos Wealth Management Inc. now owns 202,747 shares of the company’s stock worth $4,852,000 after purchasing an additional 196,884 shares during the period. Finally, OP Asset Management Ltd bought a new position in shares of Elanco Animal Health in the first quarter worth approximately $8,171,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Featured Articles

• Five stocks we like better than Elanco Animal Health
• The AI Boom Is Turning This Cable Maker Into a Stock to Watch
• A Star Investor Just Trimmed Amazon—Here’s What It means
• Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
• Home Depot Analysts See a Path to $375 and Beyond

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.